These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 17066158

  • 21. Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis.
    Sprenger R, Sagmeister M, Offner F.
    Gut; 2005 Mar; 54(3):438-9; author reply 439. PubMed ID: 15710996
    [No Abstract] [Full Text] [Related]

  • 22. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
    Yang WS, Chu PL, Liu CH, Chung GB, Wu KD.
    J Clin Gastroenterol; 2008 Jan; 42(1):112-3. PubMed ID: 18097301
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C.
    Condat B, Asselah T, Zanditenas D, Estampes B, Cohen A, O'Toole D, Bonnet J, Ngo Y, Marcellin P, Blazquez M.
    Eur J Gastroenterol Hepatol; 2006 Mar; 18(3):287-9. PubMed ID: 16462543
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan.
    Aziz H, Gil ML, Waheed Y, Adeeb U, Raza A, Bilal I, Athar MA.
    Infect Genet Evol; 2011 Apr; 11(3):640-5. PubMed ID: 21316487
    [Abstract] [Full Text] [Related]

  • 26. Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report.
    Gamal N, Brodosi L, Misciali C, Patrizi A, Vukatana G, Malavolta N, Bernardi M, Andreone P.
    Ann Hepatol; 2014 Apr; 13(2):293-6. PubMed ID: 24558223
    [Abstract] [Full Text] [Related]

  • 27. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J.
    J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
    [Abstract] [Full Text] [Related]

  • 28. [Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C].
    Lee YN, Jeong SW, Lim JH, Ryu YS, Jeon SR, Kim SK, Jang JY, Kim YS, Kim BS, Roh MO.
    Korean J Hepatol; 2010 Jun; 16(2):187-91. PubMed ID: 20606504
    [Abstract] [Full Text] [Related]

  • 29. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study [KULDS] Group.
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185
    [Abstract] [Full Text] [Related]

  • 30. Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Hayashi M, Kataoka Y, Tachikawa K, Koguchi H, Tanaka H.
    Diabetes Res Clin Pract; 2009 Nov; 86(2):e19-21. PubMed ID: 19744739
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M, Hernàndez J, Arenas MD, Carnicer F, Caramelo C, Fabrizi F.
    Kidney Blood Press Res; 2015 Nov; 40(3):258-65. PubMed ID: 25997572
    [Abstract] [Full Text] [Related]

  • 33. Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis.
    Goel A, Bhadauria DS, Kaul A, Prasad N, Gupta A, Sharma RK, Rai P, Aggarwal R.
    Nephrology (Carlton); 2017 Sep; 22(9):706-711. PubMed ID: 27286895
    [Abstract] [Full Text] [Related]

  • 34. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR, Imoto S, Mita K, Taniguchi M, Sasase N, Muramatsu A, Kudo M, Kitai S, El-Shamy A, Hotta H, Hayashi Y.
    Digestion; 2009 Sep; 79(1):36-9. PubMed ID: 19246919
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
    Crespo M, Mira JA, Pineda JA, Van den Eynde E, Ríos-Villegas MJ, Collado A, Girón-González JA, López-Cortés LF, González-Serrano M, Rivero A, Merino D, Esteban JI.
    J Antimicrob Chemother; 2008 Oct; 62(4):793-6. PubMed ID: 18567911
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN.
    Vabo IL, Ferreira LE, Pace FH.
    Arq Gastroenterol; 2016 Oct; 53(1):20-4. PubMed ID: 27281500
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.
    Hu CC, Lin CL, Kuo YL, Chien CH, Chen SW, Yen CL, Lin CY, Chien RN.
    Aliment Pharmacol Ther; 2013 Jan; 37(1):81-90. PubMed ID: 23121150
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.